AIMS/HYPOTHESIS: Serum albumin concentrations may be associated with future risk of type 2 diabetes, but the epidemiological evidence is limited and uncertain. We prospectively assessed the association between baseline values of serum albumin and incident type 2 diabetes risk in the Kuopio Ischaemic Heart Disease population-based cohort study. METHODS: We analysed the data of 1,785 men aged 42-61 years with no known history of diabetes at baseline. Participants' serum albumin concentrations were measured at baseline. HRs and 95% CIs for type 2 diabetes events were subsequently assessed. RESULTS: During a mean follow-up of 20.4 years, 382 participants developed diabetes. Serum albumin concentrations were weakly correlated with several established risk factors for diabetes. Serum albumin was approximately linearly associated with type 2 diabetes risk. In analyses adjusted for several conventional risk factors, the HR for type 2 diabetes per 1 SD increase in serum albumin was 1.15 (95% CI 1.03, 1.28; p = 0.016), which persisted after further adjustment for triacylglycerol, C-reactive protein, γ-glutamyltransferase, estimated glomerular filtration rate and total energy intake (HR 1.15; 95% CI 1.02, 1.29; p = 0.018). The findings were generally consistent across several clinical subgroups. Addition of information on serum albumin to a diabetes risk prediction model containing conventional risk factors led to no significant change in C-index (0.0126; 95% CI -0.0055, 0.0306; p = 0.17). CONCLUSIONS/ INTERPRETATION: A near linear, positive and independent association was found between serum albumin and type 2 diabetes, but this did not improve event discrimination. Further work is warranted to evaluate the causal relevance of these findings.
AIMS/HYPOTHESIS: Serum albumin concentrations may be associated with future risk of type 2 diabetes, but the epidemiological evidence is limited and uncertain. We prospectively assessed the association between baseline values of serum albumin and incident type 2 diabetes risk in the Kuopio Ischaemic Heart Disease population-based cohort study. METHODS: We analysed the data of 1,785 men aged 42-61 years with no known history of diabetes at baseline. Participants' serum albumin concentrations were measured at baseline. HRs and 95% CIs for type 2 diabetes events were subsequently assessed. RESULTS: During a mean follow-up of 20.4 years, 382 participants developed diabetes. Serum albumin concentrations were weakly correlated with several established risk factors for diabetes. Serum albumin was approximately linearly associated with type 2 diabetes risk. In analyses adjusted for several conventional risk factors, the HR for type 2 diabetes per 1 SD increase in serum albumin was 1.15 (95% CI 1.03, 1.28; p = 0.016), which persisted after further adjustment for triacylglycerol, C-reactive protein, γ-glutamyltransferase, estimated glomerular filtration rate and total energy intake (HR 1.15; 95% CI 1.02, 1.29; p = 0.018). The findings were generally consistent across several clinical subgroups. Addition of information on serum albumin to a diabetes risk prediction model containing conventional risk factors led to no significant change in C-index (0.0126; 95% CI -0.0055, 0.0306; p = 0.17). CONCLUSIONS/ INTERPRETATION: A near linear, positive and independent association was found between serum albumin and type 2 diabetes, but this did not improve event discrimination. Further work is warranted to evaluate the causal relevance of these findings.
Authors: M I Schmidt; B B Duncan; A R Sharrett; G Lindberg; P J Savage; S Offenbacher; M I Azambuja; R P Tracy; G Heiss Journal: Lancet Date: 1999-05-15 Impact factor: 79.321
Authors: Emanuele Di Angelantonio; Pei Gao; Hassan Khan; Adam S Butterworth; David Wormser; Stephen Kaptoge; Sreenivasa Rao Kondapally Seshasai; Alex Thompson; Nadeem Sarwar; Peter Willeit; Paul M Ridker; Elizabeth L M Barr; Kay-Tee Khaw; Bruce M Psaty; Hermann Brenner; Beverley Balkau; Jacqueline M Dekker; Debbie A Lawlor; Makoto Daimon; Johann Willeit; Inger Njølstad; Aulikki Nissinen; Eric J Brunner; Lewis H Kuller; Jackie F Price; Johan Sundström; Matthew W Knuiman; Edith J M Feskens; W M M Verschuren; Nicholas Wald; Stephan J L Bakker; Peter H Whincup; Ian Ford; Uri Goldbourt; Agustín Gómez-de-la-Cámara; John Gallacher; Leon A Simons; Annika Rosengren; Susan E Sutherland; Cecilia Björkelund; Dan G Blazer; Sylvia Wassertheil-Smoller; Altan Onat; Alejandro Marín Ibañez; Edoardo Casiglia; J Wouter Jukema; Lara M Simpson; Simona Giampaoli; Børge G Nordestgaard; Randi Selmer; Patrik Wennberg; Jussi Kauhanen; Jukka T Salonen; Rachel Dankner; Elizabeth Barrett-Connor; Maryam Kavousi; Vilmundur Gudnason; Denis Evans; Robert B Wallace; Mary Cushman; Ralph B D'Agostino; Jason G Umans; Yutaka Kiyohara; Hidaeki Nakagawa; Shinichi Sato; Richard F Gillum; Aaron R Folsom; Yvonne T van der Schouw; Karel G Moons; Simon J Griffin; Naveed Sattar; Nicholas J Wareham; Elizabeth Selvin; Simon G Thompson; John Danesh Journal: JAMA Date: 2014-03-26 Impact factor: 56.272
Authors: Stephen Kaptoge; Emanuele Di Angelantonio; Lisa Pennells; Angela M Wood; Ian R White; Pei Gao; Matthew Walker; Alexander Thompson; Nadeem Sarwar; Muriel Caslake; Adam S Butterworth; Philippe Amouyel; Gerd Assmann; Stephan J L Bakker; Elizabeth L M Barr; Elizabeth Barrett-Connor; Emelia J Benjamin; Cecilia Björkelund; Hermann Brenner; Eric Brunner; Robert Clarke; Jackie A Cooper; Peter Cremer; Mary Cushman; Gilles R Dagenais; Ralph B D'Agostino; Rachel Dankner; George Davey-Smith; Dorly Deeg; Jacqueline M Dekker; Gunnar Engström; Aaron R Folsom; F Gerry R Fowkes; John Gallacher; J Michael Gaziano; Simona Giampaoli; Richard F Gillum; Albert Hofman; Barbara V Howard; Erik Ingelsson; Hiroyasu Iso; Torben Jørgensen; Stefan Kiechl; Akihiko Kitamura; Yutaka Kiyohara; Wolfgang Koenig; Daan Kromhout; Lewis H Kuller; Debbie A Lawlor; Tom W Meade; Aulikki Nissinen; Børge G Nordestgaard; Altan Onat; Demosthenes B Panagiotakos; Bruce M Psaty; Beatriz Rodriguez; Annika Rosengren; Veikko Salomaa; Jussi Kauhanen; Jukka T Salonen; Jonathan A Shaffer; Steven Shea; Ian Ford; Coen D A Stehouwer; Timo E Strandberg; Robert W Tipping; Alberto Tosetto; Sylvia Wassertheil-Smoller; Patrik Wennberg; Rudi G Westendorp; Peter H Whincup; Lars Wilhelmsen; Mark Woodward; Gordon D O Lowe; Nicholas J Wareham; Kay-Tee Khaw; Naveed Sattar; Chris J Packard; Vilmundur Gudnason; Paul M Ridker; Mark B Pepys; Simon G Thompson; John Danesh Journal: N Engl J Med Date: 2012-10-04 Impact factor: 91.245
Authors: Setor K Kunutsor; Ari Voutilainen; Michael R Whitehouse; Samuel Seidu; Jussi Kauhanen; Ashley W Blom; Jari A Laukkanen Journal: Med Princ Pract Date: 2019-03-21 Impact factor: 1.927
Authors: Nga Phi Thi Nguyen; Thuc Luong Cong; Binh Thanh Vu; Tuan Dinh Le; Thi Thanh Hoa Tran; Binh Nhu Do; Son Tien Nguyen; Lan Ho Thi Nguyen; Manh Van Ngo; Hoa Trung Dinh; Hoang Duong Huy; Nghia Xuan Vu; Kien Nguyen Trung; Duong Ngoc Vu; Nghia The Pham Journal: Int J Gen Med Date: 2022-03-08
Authors: Setor Kwadzo Kunutsor; Michael Richard Whitehouse; Ashley William Blom; Jari Antero Laukkanen Journal: Eur J Epidemiol Date: 2017-04-12 Impact factor: 8.082